Cisplatin has dramatically improved the survival rate of cancer patients, but it has also
increased the prevalence of hearing and neurological deficits in this population. Cisplatin …

In addition to the anti-diabetic effect of metformin, a growing number of studies have shown
that metformin has some exciting properties, such as anti-oxidative capabilities, anticancer …

Although targeting oxidative phosphorylation (OXPHOS) is a rational anticancer strategy,
clinical benefit with OXPHOS inhibitors has yet to be achieved. Here we advanced IACS …

Background Chemotherapy is a standard therapeutic regimen to treat triple-negative breast
cancer (TNBC); however, chemotherapy alone does not result in significant improvement …

Bortezomib, a first-generation proteasome inhibitor widely used in chemotherapy for
hematologic malignancy, has effective anti-cancer activity but often causes severe …

Chemotherapy-induced peripheral neuropathy (CIPN), characterized by pain and numbness
in hands and feet, is a common side effect of cancer treatment. In most patients, symptoms of …

Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a progressive,
enduring, and often irreversible adverse effect of many antineoplastic agents, among which …

Chemotherapy-induced peripheral neuropathy is one of the most common dose-limiting side
effects of cancer treatment. Currently, there is no Food and Drug Administration–approved …

Chemotherapy‐induced peripheral neuropathy (CIPN) is a serious adverse side effect of
many chemotherapeutic agents, affecting> 60% of patients with cancer. Moreover, CIPN …

Metformin is a widely prescribed drug used in the treatment of type II diabetes. While the
drug has many mechanisms of action, most of these converge on AMP activated protein …